Medications for neurodegenerative diseases

7,742views

Medications for neurodegenerative diseases

M1 Beweging

M1 Beweging

Transient ischemic attack
Stroke: Clinical
Ischemic stroke
Cardiovascular system anatomy and physiology
Introduction to the cardiovascular system
Migraine
Migraine medications
Dizziness and vertigo: Clinical
Headaches: Clinical
Headaches: Pathology review
Seizures: Clinical
Anatomy of the brainstem
Tension headache
Cluster headache
Anatomy clinical correlates: Temporal regions, oral cavity and nose
Bruxism
Trigeminal neuralgia
Anatomy of the trigeminal nerve (CN V)
Sturge-Weber syndrome
Cranial nerves
Peripheral nervous system histology
Central nervous system histology
Ulnar claw
Anatomy clinical correlates: Median, ulnar and radial nerves
Brachial plexus
Vessels and nerves of the forearm
Carpal tunnel syndrome
Anatomy of the arm
Anatomy of the brachial plexus
Muscle weakness: Clinical
Polymyalgia rheumatica
Guillain-Barre syndrome
Demyelinating disorders: Pathology review
Parkinson disease
Anti-parkinson medications
Hypokinetic movement disorders: Clinical
Movement disorders: Pathology review
Seizures and epilepsy
Seizures: Pathology review
Nonbenzodiazepine anticonvulsants
Tourette syndrome
Fragile X syndrome
Hyperkinetic movement disorders: Clinical
Disorders of consciousness: Clinical
Consciousness
Meningitis
Meningitis, encephalitis and brain abscesses: Clinical
Neisseria meningitidis
Central nervous system infections: Pathology review
West Nile virus
Streptococcus pneumoniae
Back pain: Pathology review
Spinal disc herniation
Degenerative disc disease
Sciatica
Brain herniation
Dissociative disorders
Dissociative disorders: Clinical
Anatomy clinical correlates: Vertebral canal
Cauda equina syndrome
Spinal stenosis
Spinal cord reflexes
Spinal cord disorders: Pathology review
Tethered spinal cord syndrome
Ascending and descending spinal tracts
Anatomy of the ascending spinal cord pathways
Anatomy of the descending spinal cord pathways
Anatomy clinical correlates: Spinal cord pathways
Multiple sclerosis
Amyotrophic lateral sclerosis
Normal pressure hydrocephalus
Aqueductal stenosis
Chiari malformation
Dandy-Walker malformation
Congenital neurological disorders: Pathology review
Dementia and delirium: Clinical
Epidural hematoma
Epidural abscess
Subdural hematoma
Traumatic brain injury: Clinical
Adult brain tumors
Brain tumors: Clinical
Adult brain tumors: Pathology review
Neurofibromatosis
Pediatric brain tumors: Pathology review
Brown-Sequard Syndrome
Vertigo: Pathology review
Serotonin and norepinephrine reuptake inhibitors
DNA synthesis inhibitors: Fluoroquinolones
DNA synthesis inhibitors: Metronidazole
Tricyclic antidepressants
Anatomy of the blood supply to the brain
Brain abscess
Anatomy of the cerebral cortex
Motor cortex
Cerebral palsy
Cerebral circulation
Anatomy clinical correlates: Cerebral hemispheres
Cerebral vascular disease: Pathology review
Anatomy of the spinal accessory (CN XI) and hypoglossal (CN XII) nerves
Nervous system anatomy and physiology
Development of the muscular system
Vestibular transduction
Vestibulo-ocular reflex and nystagmus
Alport syndrome
Homocystinuria
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Anatomy and physiology of the eye
Eye and ear histology
Eye conditions: Retinal disorders: Pathology review
Anatomy of the eye
Eye conditions: Inflammation, infections and trauma: Pathology review
Development of the eye
Optic pathways and visual fields
Pediatric ophthalmological conditions: Clinical
Cataract
Glaucoma
Retinal detachment
Age-related macular degeneration
Diabetic retinopathy
Diabetic nephropathy
Anatomy clinical correlates: Eye
Uveitis
Photoreception
Congenital heart defects: Clinical
Congenital disorders: Clinical
Congenital gastrointestinal disorders: Pathology review
Club foot
Pediatric orthopedic conditions: Clinical
Osgood-Schlatter disease (traction apophysitis)
Lordosis, kyphosis, and scoliosis
Dislocated shoulder
Anatomy clinical correlates: Clavicle and shoulder
Patellofemoral pain syndrome
Rotator cuff tear
Bursitis
Seronegative and septic arthritis: Pathology review
Seronegative arthritis: Clinical
Rheumatoid arthritis: Clinical
Rheumatoid arthritis and osteoarthritis: Pathology review
Septic arthritis
Rheumatoid arthritis
Reactive arthritis
Psoriatic arthritis
Juvenile idiopathic arthritis
Subacute granulomatous thyroiditis
Radial head subluxation (Nursemaid elbow)
Anatomy of the knee joint
Meniscus tear
Anterior cruciate ligament injury
Osteoarthritis
Joint pain: Clinical
Temporomandibular joint dysfunction
Patellar tendon rupture
Muscle spindles and golgi tendon organs
Baker cyst
Deep vein thrombosis and pulmonary embolism: Pathology review
Spondylolysis
Spondylolisthesis
Lower back pain: Clinical
Spondylosis
Spondylitis
Muscles of the back
Legg-Calve-Perthes disease
Cleidocranial dysplasia
Metaplasia and dysplasia
Developmental dysplasia of the hip
Achilles tendon rupture
Charcot-Marie-Tooth disease
Anatomy of the foot
Joints of the ankle and foot
Flat feet
Genu valgum
Anatomy clinical correlates: Foot
Sprained ankle
Attention deficit hyperactivity disorder
Generalized anxiety disorder
Sleep disorders: Clinical
Major depressive disorder
Social anxiety disorder
Disruptive, impulse-control and conduct disorders: Clinical
Obsessive compulsive disorders: Clinical
Obsessive-compulsive disorder
Personality disorders: Clinical
Somatic symptom disorders: Clinical
Panic disorder
Mood disorders: Pathology review
Mood disorders: Clinical
Major depressive disorder with seasonal pattern
Cluster B personality disorders
Childhood and early-onset psychological disorders: Pathology review
Delirium
ADHD: Information for patients and families (The Primary School)
Psychomotor stimulants
Sympatholytics: Alpha-2 agonists
Neurodevelopmental disorders: Clinical
Autism spectrum disorder
Substance misuse and addiction: Clinical
Cocaine use disorder
Suicide
Opioid antagonists
Opioid agonists, mixed agonist-antagonists and partial agonists
Local anesthetics
Tobacco use disorder
Malingering, factitious disorders and somatoform disorders: Pathology review
Somatic symptom disorder
Cluster C personality disorders
Cluster A personality disorders
Eating disorders: Clinical
Body focused repetitive disorders
Delusional disorder
Schizophrenia spectrum disorders: Clinical
Schizophrenia
Lithium
Atypical antipsychotics
Typical antipsychotics
Schizophrenia spectrum disorders: Pathology review
Personality disorders: Pathology review
Disruptive, impulse control, and conduct disorders
Post-traumatic stress disorder
Trauma- and stress-related disorders: Pathology review
Stress
Anxiety disorders, phobias and stress-related disorders: Pathology Review
Selective serotonin reuptake inhibitors
Medications for neurodegenerative diseases
Atypical antidepressants
Anticonvulsants and anxiolytics: Benzodiazepines
Toxidromes: Clinical
Insomnia
Gout
Gout and pseudogout: Pathology review
Non-steroidal anti-inflammatory drugs
Antigout medications
Lupus nephritis
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE): Clinical
Antiphospholipid syndrome
Fibromyalgia
Myalgias and myositis: Pathology review
Intracerebral hemorrhage
Subarachnoid hemorrhage

Transcript

Watch video only

Huntington disease, or HD, is a rare neurodegenerative disease that involves a repeated sequence of DNA that causes an abnormal protein to form, leading to abnormal movements and cognitive problems.

In most people, a gene called huntingtin or HTT on chromosome 4, contains a triplet repeat, where the nucleotides C, A, and G are repeated 10-35 times in a row. In people with Huntington disease, this repeat goes on for 36 or more times in a row.

CAG codes for the amino acid glutamine, so people with Huntington disease will have 36 or more glutamines in a row in the huntingtin protein.

So, in addition to being a triplet repeat disorder, HD is, more specifically, a “polyglutamine” disease.

The specific way in which extra glutamines causes HD symptoms isn’t fully worked out, but some clues are that the mutated protein aggregates within the neuronal cells of the caudate and putamen of the basal ganglia causing neuronal cell death.

Cell death might be related to excitotoxicity, which is excessive signaling of these neurons, which leads to high intracellular calcium.

Now the symptoms of HD involve progressive CNS disturbances including movement, cognitive, and mood symptoms and they start appearing around the age of 40.

Remember, the age of onset depends on the number of CAG repeats, so more repeats means earlier onset.

Over time, if enough of the neurons die in the caudate and putamen, which together form the dorsal striatum, then it can cause actual loss of brain tissue volume in that area and expansion of the lateral ventricles.

The death of neurons also cause neurotransmitter imbalance in these regions and there’s a decrease in inhibitory neurotransmitters like GABA, and an increase in stimulatory neurons like dopamine.

This also decreases acetylcholine, which is released by interneurons that help other neurons communicate.

Now, the affected areas play an important role in movement, particularly inhibiting it, so cell death in the basal ganglia causes movement problems like chorea, which are purposeless, dance-like jerking movements, and athetosis which are slower, writhing, “snake-like” movements mainly affecting the hands.

These involuntary movements can’t be consciously suppressed and stop only with sleep.

Other motor problems include abnormal eye movements and poor coordination.

Loss of tissue in these regions can also lead to psychological problems as well.

These people often experience psychosis and agitation, leading to disruptive behavior, and mood disorders like major depressive disorder.

They might also develop dementia and severe cognitive defects.

Since the muscles for swallowing become discoordinated, these people often suffer from dysphagia and aspiration pneumonia.

Unfortunately, there is no treatment to stop or reverse Huntington disease, and death usually happens within 10-20 years of diagnosis, often by aspiration pneumonia or suicide.

The medications used for Huntington disease are focused around managing the symptoms like chorea, and psychosis.

Since dopamine is increased in the regions of the brain affected, medications that lower dopamine levels or act as antagonists are usually used. These include tetrabenazine, and antipsychotics.

Let’s start with tetrabenazine and its deuterated form, deutetrabenazine.

Deuterated simply means some of the hydrogen molecules in the medication have been replaced by the more stable deuterium isotope to improve the half life of the drug.

These medications work on both presynaptic and postsynaptic neurons.

In the presynaptic neuron, they block vesicular monoamine transporters, or VMAT found on the vesicles.

These transport proteins allow dopamine into the vesicles for storage, so when they are inhibited, the vesicles can’t release dopamine into the synaptic cleft.

Next, on the postsynaptic neuron, these medications act as a weak dopamine receptor antagonist, so they bind to the receptors and prevent dopamine from binding.

Tetrabenazine and deutetrabenazine are often used for the treatment of chorea in Huntington disease. However, they are also useful for treating Tourette’s syndrome, which is a neurological disorder characterized by repetitive, involuntary movements and vocalizations called tics.

Key Takeaways

There are a few different types of medications that can be prescribed for neurodegenerative diseases. One common type is called cholinesterase inhibitors, which work by preventing the breakdown of the neurotransmitter acetylcholine. This type of medication can help to improve cognitive function and memory in people with Alzheimer's disease.

Another common type of medication for neurodegenerative diseases is NMDA receptor blockers. This type of medication helps to prevent damage to nerve cells by blocking the action of glutamate, a chemical that can be harmful to nerve cells. Blocking glutamate can help to preserve nerve function and reduce symptoms in people with conditions such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Deuterium Tetrabenazine for Tardive Dyskinesia" Clin Schizophr Relat Psychoses (2018)
  5. "Huntington's Disease-Update on Treatments" Curr Neurol Neurosci Rep (2017)
  6. "Antipsychotic drugs in Huntington's disease" Expert Rev Neurother (2017)